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INTRODUCTION
Improvements in outcome for children with acute lympho-
blastic leukemia (ALL) have been dramatic. Nevertheless front-
line therapy has failed in up to 25% of children with relapsed
or refractory form, and their long-term prognosis is poor (1,
2). Aiming for complete remission by intensive chemother-
apy is essential, in order to cure relapsed ALL and ensure the
long-term survival of the patients with relapsed ALL (3, 4).
Although the schedules were diverse, many induction ch-
emotherapy regimens for relapsed ALL have consisted of vin-
cristine, corticosteroid, L-asparaginase, and anthracycline (1,
5-7). Idarubicin (4-demethoxydaunorubicin) was introduced
as a new anthracycline which is superior to daunomycin in
the treatment of acute myeloid leukemia (8-10). It has shown
promise in the treatment of relapsed ALL in children because
it is more effective in multidrug-resistant cell lines and has
relatively low cardiotoxicity, but a high penetration rate to
central nervous system (CNS), compared with daunorubicin
or doxorubicin (8, 11, 12). Idarubicin has been widely used
recently to treat acute myeloid leukemia or relapsed/refrac-
tory ALL, and other kinds of malignancy. 
The maximum tolerated dose (MTD) of idarubicin used as
a single agent to treat a childhood leukemia is between 30 and
40 mg/m2 as a total dose when administered on 3 consecutive
days (13). But in combination with other chemotherapeutic
agents, MTD is variable according to kinds and doses of other
chemotherapeutic agents in combination, and the chemother-
apy schedule. The Children’s Cancer Study Group (CCG) st-
udy to determine the MTD of weekly idarubicin in multidrug
induction combination chemotherapy for relapsed ALL, and
the study to compare the effect and toxicity of high (12.5 mg/
m2) and intermediate (10 mg/m2) doses of idarubicin, deter-
mined that the optimal dose of weekly idarubicin in induc-
tion combination chemotherapy for relapsed ALL was 12.5
mg/m2 according to the CCG protocol for chemotherapy of
relapsed ALL (CCG-1884) (14, 15). The weekly dose of idaru-
bicin was 12.5 mg/m2 based on this induction chemotherapy
protocol initially, because no study has established the opti-
mal weekly dose of idarubicin for the treatment of relapsed
ALL in Korean children. However this dose was highly toxic
for many patients leading to treatment-related mortality (TRM)
and a lower remission rate than that reported in a previous
CCG study. Thus the weekly dose of idarubicin was reduced
to 10 mg/m2, and we observed a better remission rate and lo-
wer toxicity with 10 mg/m2 than 12.5 mg/m2. Therefore, we
postulated that a weekly idarubicin dose of 12.5 mg/m2in this
multidrug combination induction chemotherapy was inad-
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Improvement of Induction Remission Rate by Modifying the Dose of
Idarubicin for Relapsed Childhood Acute Lymphoblastic Leukemia
Relapse is the major cause of treatment failure in acute lymphoblastic leukemia (ALL),
yet there is no established treatment for relapsed ALL. To improve the induction remis-
sion rate, we modified the dose of idarubicin in the original Children’s Cancer Group
(CCG)-1884 protocol, and retrospectively compared the results. Twenty-eight patients
diagnosed with relapsed ALL received induction chemotherapy according to the
CCG-1884 protocol. Complete remission (CR) rate in all patients after induction ch-
emotherapy was 57%. The idarubicin 10 mg/m
2/week group showed CR rate of 74%,
compared with the 22% CR rate of the idarubicin 12.5 mg/m
2/week group (p=0.010).
Remission failure due to treatment-related mortality (TRM) was 44% and 5.2% in
the idarubicin 12.5 mg/m
2/week and 10 mg/m
2/week groups, respectively (p=0.011).
Overall survival (OS) and 4-yr event-free survival (EFS) were 12.8% and 10.3%,
respectively. OS and 4-yr EFS were higher in the idarubicin 10 mg/m
2/week group
(19.3% and 15.6%) than in the 12.5 mg/m
2/week group (0% and 0%). In conclusion,
a modified dose of idarubicin from 12.5 mg/m
2/week to 10 mg/m
2/week resulted in
an improved CR rate in the treatment of relapsed ALL, which was due to lower TRM.
However, despite improved CR rate with modified dose of idarubicin, survival rates
were unsatisfactory.
Key Words : Idarubicin; Remission Induction; Recurrence; Precursor Cell Lymphoblastic Leukemia-Lymphoma
Received : 29 October 2007
Accepted : 10 June 2008equate and too toxic to Korean children with relapsed ALL,
and that a reduced dose of idarubicin (10 mg/m2) may be opti-
mal for them. The aim of this study was to evaluate the im-
provement in induction remission rate after modifying the
idarubicin dose in the induction regimen for relapsed ALL
(CCG-1884) retrospectively and to determine the more opti-
mal dose of idarubicin in induction chemotherapy for relapsed
ALL in Korean children.
MATERIALS AND METHODS
Patient populations
Pediatric patients who were diagnosed with relapsed ALL,
and treated according to the CCG-1884 induction protocol,
which consisted of prednisolone, vincristine, L-asparaginase,
idarubicin as anthracycline in Seoul National University Chil-
dren’s Hospital were enrolled in this study between 1 January
1995 and 31 May 2005. Patients who received daunorubicin
as anthracycline were excluded. Medical records of these pa-
tients were reviewed retrospectively.
Treatment progression
All patients were admitted and had a bone marrow (BM)
examination before initiation of induction chemotherapy. 
The original CCG-1884 protocol consisted of oral pred-
nisolone 40 mg/m2/day for 28 days, weekly intravenous (IV)
vincristine 1.5 mg/m2, intramuscular L-asparaginase 6,000
IU/m2 thrice weekly with a total of 9 doses, and weekly IV
idarubicin on day 0, 7, 14 (Table 1). We used a modified pro-
tocol which increased the daily dose of prednisolone to 60 mg/
m2/day and permitted addition of idarubicin on day 21 (Table
1). If complete blood count (CBC) on day 14 or day 21 showed
absolute neutrophil count (ANC) <500/μ L or platelet count
<50,000/μ L, IV administration of idarubicin was withdrawn.
The dose of idarubicin was modified from 1 June 1999. Before
31 May 1999, the dose of weekly IV idarubicin was 12.5 mg/
m2 according to CCG protocol, but after June 1999, we re-
duced the dose of weekly idarubicin to 10 mg/m2. For CNS
prophylaxis, hydrocortisone and cytosine arabinoside were
injected intrathecally on days 0, 7, and 28, respectively. All
patients with leukemic CNS involvement on diagnosis as re-
lapse had intrathecal chemotherapy with hydrocortisone and
cytosine arabinoside on days 0, 7, 14, 21, and 28.
If a patient had fever or other symptoms suspected treat-
ment-related complication, such as infection or septic shock,
chemotherapy was stopped and IV antibiotics and other sup-
portive cares for complications were started. 
After the completion of induction chemotherapy, the BM
of all patients was examined. If patients showed complete re-
mission on the day 28 bone marrow examination, they con-
tinued maintenance chemotherapy or stem cell transplanta-
tion as autologous a matched, sibling, or unrelated donor be-
came available. In spite of a different weekly dose of idarubicin,
all patients had the same maintenance (CCG-1884 mainte-
nance protocol) chemotherapy before and after June 1999.
Supportive care in both groups did not differ significantly.
The final outcome of treatment was divided into three cat-
egories: living without relapse, treatment failure (persistence
or relapse after remission), and TRM.
Statistical analysis
Comparability of both groups (idarubicin 12.5 mg/m2 and
idarubicin 10 mg/m2) was examined by the Pearson chi-square
homogeneity test for several available potentially important
factors and presenting features. Statistical significance was de-
fined as p value less than 0.05.
The duration of overall survival (OS) was defined as the peri-
od between the date of diagnosis of relapse and either the date
of death or the date of the most recent follow-up. The dura-
tion of event-free survival (EFS) was defined as the period be-
tween the date of diagnosis of relapse and either the date of
diagnosis of persistence of leukemia on BM examination or
relapse, the date of the most recent follow-up, or the date of
treatment-related death. Probabilities of OS and EFS were
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IM, intramuscular; IV, intravenous; ANC, absolute neutrophil count; IT, intrathecal; Ara-C, cytosine arabinoside; HC, hydrocortisone.
Original CCG-1884 induction chemotherapy
Prednisolone (40 mg/m
2, oral) Days 0-27, then taper
Vincristine (1.5 mg/m
2, IV) Days 0, 7, 14, 21
L-asparaginase (6,000 IU/m
2, IM) Thrice weekly, total 9 doses
Idarubicin (12.5 mg/m
2, IV) Days 0, 7, 14 
CNS therapy
No CNS involvement IT Ara-C and HC Day 0, 7, 28
CNS involvement IT Ara-C and HC Day 0, 7, 14, 21, 28
Table 1. Induction chemotherapy schedule: original CCG-1884 induction (A) and modified CCG-1884 induction (B) schedule in Seoul
National University Children’s Hospital
(A)
Modified CCG-1884 induction chemotherapy
Prednisolone (60 mg/m
2, oral) Days 0-27, then taper
Vincristine (1.5 mg/m
2, IV) Days 0, 7,14, 21
L-asparaginase (6,000 IU/m
2, IM) Thrice weekly, total 9 doses
Idarubicin (10 or 12.5 mg/m
2, IV) Days 0, 7,14, 21
(if ANC ≥500/μ L and platelet count ≥50,000/μ L on day 14 and 21)
CNS therapy
No CNS involvement IT Ara-C and HC Day 0, 7, 28
CNS involvement IT Ara-C and HC Day 0, 7, 14, 21, 28
(B)estimated using the Kaplan-Meier method and the log rank
test was used to compare proportions. SPSS 12.0 software was
used for the statistical analysis.
RESULTS
Patient characteristics
A total of 28 patients (17 males and 11 females) were enroll-
ed in this study. Nine patients were in the 12.5 mg/m2 idaru-
bicin dose gourp (Ida 12.5 mg/m2), and 19 were in the 10
mg/m2 idarubicin dose group (Ida 10 mg/m2). The median
age of the patients was 8 yr 11 months (from 11 months to
18 yr). Median ages of each group were 10 yr 11 months (from
2 yr 5 months to 14 yr 7 months) in the Ida 12.5 mg/m2group
and 7 yr 8 months (from 11 months to 15 yr 6 months) in the
Ida 10 mg/m2 group.
Numbers of relapse site in the patients at study entry were:
23 at BM only, 4 at BM and CNS, and 1 at BM and testis.
Comparisons of patient characteristics in both groups are
set out in Table 2. There were no significant differences be-
tween the 2 groups with respect to white blood cell (WBC),
age, gender, CD10 positivity, or duration of previous remission.
Treatment progression
Of 9 patients on a weekly dose of idarubicin 12.5 mg/m2,
5 completed induction chemotherapy and 4 died due to treat-
ment-related sepsis or infection. Of 5 patients who had com-
plete induction chemotherapy, 2 showed complete remission
(CR) at bone marrow examination, but 3 showed persistence
of leukemia. But the 2 patients with CR after induction ch-
emotherapy had relapsed again during maintenance chemo-
therapy.
Of 19 patients on a weekly dose of idarubicin 10 mg/m2,
18 completed induction chemotherapy, and 1 died because
of treatment-related infection. Of 18 patients who complet-
ed induction chemotherapy, 4 showed persistence of leukemia
and 14 had CR. Post-remission treatments in 14 patients with
remission were: 9 received only maintenance chemotherapy,
1 had autologous peripheral stem cell transplantation, 2 had
bone marrow transplantation (BMT) from sibling donors, 1
had BMT from an unrelated donor, and 1 patient had cord
blood transplantation. Among them, only 4 patients, includ-
ing 1 patient who had allogeneic BMT and 3 who received
only maintenance chemotherapy, showed a continuous state
of remission, and 10 had relapsed (Fig. 1).
Treatment results
CR rate in all patients after induction chemotherapy accord-
ing to the modified CCG-1884 protocol was 57% (16/28).
CR rates were 22% (2/9) in the Ida 12.5 mg/m2 group and
74% (14/19) in the Ida 10 mg/m2 group (significant at p=
0.010). Compared with the patients who completed induc-
tion chemotherapy, the Ida 12.5 mg/m2group showed a lower
CR rate (2/5, 40%) than the Ida 10 mg/m2 group (14/18, 78
%), but it was not statistically significant (p=0.104).
TRM was 44% (4/9) and 5.2% (1/19) in the Ida 12.5 mg/
m2 group and Ida 10 mg/m2, respectively. The Ida 10 mg/m2
group showed lower TRM (significant at p=0.011). 
OS of the total patients was 12.8%, and 4-yr EFS of the
total group was 10.3% (Fig. 2). OS and 4-yr EFS of the patients
who had CR after induction were 26.2% and 18.2%, respec-
tively (Fig. 3). Comparing the estimates of survival rates be-
tween the Ida 12.5 mg/m2and Ida 10 mg/m2groups, OS and
4-yr EFS in each group were both 0% in the Ida 12.5 mg/m2
group, and 19.3% and 15.6% in the Ida 10 mg/m2 group
(Fig. 4). In the Ida 12.5 mg/m2 group, no patient survived
long-term as a result of relapse or treatment-related compli-
cation. There was statistical significance in OS between two
groups (p=0.00001), but not in EFS (p=0.0858). 
DISCUSSION
Idarubicin is an analog of daunorubicin, and an effective
agent for relapsed ALL (13, 14). In the treatment of relapsed
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Ida Ida 
p value
12.5 mg/m
2 10 mg/m
2
WBC at study entry
<10,000/μ L 5 13 0.123
10,000-49,000/μ L1 5
≥50,000/μ L3 1
Age at relapse
<4 yr 0 2 0.066
4-9 yr 2 11
10- yr 7 6
Gender
Male 5 12 0.700
Female 4 7
Duration of previous initial remission
<1 yr 2 5 0.406
1-3 yr 6 8
>3 yr 1 6
Site of relapse
BM only 8 15 0.726
BM+CNS 1 3
BM+testis 0 1
CD10 positivity
Positive 1 3 0.741
Negative 8 16
Ida, idarubicin; WBC, white blood cell; BM, bone marrow; CNS, central
nervous system.
Table 2. Characteristics of patients and comparability in both
groupsALL, the prospective study of CCG by Feig et al. (14, 15) con-
cluded that MTD and most effective weekly dose of idarubicin
in combination induction chemotherapy (CCG-1884 induc-
tion) was 12.5 mg/m2/week. However, this dose was for West-
ern children, and there was no study on MTD and the most
effective weekly dose of idarubicin in the treatment of relapsed
ALL. This study aimed to establish whether the modification
of the weekly idarubicin dose improved the remission rate in
Korean children who were treated according to the CCG-1884
induction chemotherapy protocol, retrospectively.
The results of this study showed that a reduced weekly id-
arubicin dose of 10 mg/m2 resulted in a higher CR rate than
that of 12.5 mg/m2, due to lower TRM in the Ida 10 mg/m2
group. This result is different to that of the CCG study by Feig
et al. (15) which showed that the remission rate after CCG-
1884 induction chemotherapy was higher in the weekly idaru-
bicin 12.5 mg/m2 group (19 of 26 patients, 73%) than in the
lower idarubicin 10 mg/m2 dose group (13 of 18 patients, 72
%), without statistical significance.
In this study, the lower TRM rate is the most important
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Fig. 2. Overall survival (OS, A) and event-free survival (EFS, B) in all patients, using Kaplan-Meier method. Estimates of OS and 4-yr EFS
were 12.8% and 10.3%, respectively.
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Fig. 1. Outcomes of treatment in all patients. Dose of weekly idarubicin changed from 12.5 mg/m
2 to 10 mg/m
2 in June, 1999.
Ida, idarubicin; TRM, treatment-related mortality, maintenance; Tx., maintenance chemotherapy.
Remission (2 pts)
All relapse
during maintenance Tx.
Survival without relapse
(4 pts)
Relapse
(10 pts)
Persistence (3 pts) Remission (14 pts) Persistence (4 pts)
TRM
(4 pts)
TRM
(1 pts)
Total patients
(n=28)
Ida 12.5 mg/m
2
(9 pts)
Ida 10 mg/m
2
(19 pts)
Complete induction
(5 pts)
Complete induction
(18 pts)
Further treatmentfactor related to the improved CR rate in the Ida 10 mg/m2
group. TRM rates in induction chemotherapy were 44% and
5.3% in the Ida 12.5 mg/m2 group and Ida 10 mg/m2 group,
respectively. These results show higher TRM in the 12.5 mg/
m2 dose of weekly idarubicin, but a similar level of TRM in
the 10 mg/m2dose, compared with the previous study by Feig
et al. (15) which showed the 19% (5 of 26) and 6% (1 of 18)
of TRM in the 12.5 mg/m2and Ida 10 mg/m2groups, respec-
tively. These differences could be explained by the different
level of supportive care, with no specific evidence, but can re-
flect the fact that Korean pediatric patients with relapsed ALL
are more susceptible to the myelosuppression with high dose
idarubicin, which may indicate the importance of ethnic vari-
ation in pharmacogenetics of certain drugs. However, there
is no study on pharmacogenetics or pharmacogenomics relat-
ed to idarubicin metabolism or dose modification of idarubicin,
although some studies exist on the relationship between spe-
cific pharmacogenetics and treatment outcomes (16-18). Fur-
ther study on this topic should be investigated.
There is no consensus or study on ethnic variation of MTD
of idarubicin. What is the optimal dose of weekly idarubicin
in the therapy of relapsed ALL of Korean pediatric patient?
There is no agreement on this point. This is the first study
related to the optimal dose of idarubicin in Korea pediatric
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Fig. 3. Overall survivals (OS, A) and event-free survivals (EFS, B) between patients with or without complete remission (CR), using Kaplan-
Meier method. Estimates of OS were 26.2% and 0% (p=0.0045), and 4-yr EFS were 18.2% and 0% (p=0.000), respectively.
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Fig. 4. Overall survivals (OS, A) and event-free survivals (EFS, B) at different dose of idarubicin in induction chemotherapy, using Kaplan-Meier
method. Estimates of OS were 19.3% and 0% (p=0.00001), and 4-yr EFS were 15.6% and 0% (p=0.0858), respectively.
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2ALL patients. No previous literature discussed whether the
idarubicin dose in Western protocols for relapsed ALL is ade-
quate for Korean pediatric patients. 
Of the patients who completed induction chemotherapy,
40% and 78% of those achieved remission in the Ida 12.5
mg/m2 and 10 mg/m2 groups, respectively. The Ida 10 mg/
m2 group also showed a higher remission rate in patients who
completed induction chemotherapy, but there was no statisti-
cal significance. These results differed from those of the CCG
study by Feig et al. (15), which were 90% (19 of 21) and 76
% (13 of 17) in both groups, respectively, which showed a
higher remission rate in the higher idarubicin dose group. We
suggest that these different results relate to the higher TRM
in the high idarubicin dose (12.5 mg/m2/week) in Korean
children. The weekly dose of idarubicin 10 mg/m2 showed
that remission rates in two studies were similar, which means
that the higher dose of idarubicin 12.5 mg/m2 is not only too
toxic but also does not contribute to improvement in remis-
sion rate. The results of this study suggest at least that a high-
er 12.5 mg/m2 dose of idarubicin has no advantage in both
effect and safety.
The idarubicin dose in induction chemotherapy for relapsed
or refractory ALL was varied according to treatment protocol.
Thomson et al. (4) reported that idarubicin 10 mg/m2 given
over the initial 3 days of induction was an attempt to prevent
prolonged myelosuppression seen with weekly dosing. The
ALL-R87 study by Giona et al. (19) used the induction pro-
tocol based on daily idarubicin 5 mg/m2 with continuous in-
fusion of cytarabine 1 g/m2/day and oral prednisolone 40 mg/
m2/day for 6 days consecutively. Testi et al. (20) reported on
a single dose of idarubicin 40 mg/m2 in day 6, cytarabine 3
g/m2 continuous infusion over 3 hr for 6 days, prednisolone
40 mg/m2 for 5 days, and subsequent G-CSF 5 μ g/kg. Study
for the CHP-540 protocol by Leahney et al. (21) showed that
an induction regimen with weekly idarubicin 10 mg/m2with
dexamethasone 10 mg/m2 (day 0-28), weekly vincristine 1.5
mg/m2 and Peg-asparaginase was an effective regimen for re-
lapsed ALL, but was toxic. These diversities in doses and sc-
hedules of idarubicin as induction regimens for relapsed ALL
suggest that the optimal dosage of this chemotherapeutic agent
with more effect and less toxicity is not definite, and is deter-
mined by other factors such as other chemotherapeutic drugs
in combination with idarubicin, the schedule of idarubicin,
and subject patients. We suggest the ethnic difference as the
another factor in the determination of the optimal dose of id-
arubicin.
Another important finding in this study is that a higher
remission rate after a lower dose of weekly idarubicin (10 mg/
m2) did not guarantee higher EFS, with statistic significance.
In 14 patients with remission in the Ida 10 mg/m2group after
induction chemotherapy, 10 had a relapse of leukemia dur-
ing maintenance chemotherapy or after stem cell transplan-
tation. Of a total of 16 patients with remission after modified
CCG-1884 induction chemotherapy, 9 of 11 patients with
maintenance chemotherapy, 1 of 2 patients with related BMT,
1 patient with unrelated BMT, 1 patient with autologous pe-
ripheral stem cell transplantation, and 1 patient with cord
blood transplantation suffered a relapse. This is consistent with
a previous study by Feig et al. (15) which showed 15% of 3-
yr EFS in patients with idarubicin (12.5 mg/m2/week or 10
mg/m2/week) in CCG-1884 induction chemotherapy. These
results indicate that any present post-remission therapy result-
edin a failure to achieve good long-term survival without re-
lapse. Several reports have suggested a potential superiority
for allogeneic BMT for children with ALL who achieved a
second remission after relapse (19, 22-25). The CCG study
by Feig et al. (26) reported that BMT is superior to chemother-
apy in maintaining CR of relapsed childhood ALL treated
according to the CCG-1884 protocol, although the EFS at
24 months was higher among the patients with maintenance
chemotherapy than with transplantation (no statistical sig-
nificance), if they were treated with idarubicin in induction
chemotherapy. Although it is impossible to compare the result
according to the post-remission therapy, because of the small
number of the patient who had BMT in this study, any treat-
ment was not associated with satisfactory long-term event-free
survival. More effective and intensive post-remission therapy
should be investigated.
This is the only preliminary, retrospective study of a single
center for evaluation of the optimal dose of weekly idarubicin
in the treatment of relapsed ALL in Korean children. For eval-
uation of the precise effect of a modified dose of idarubicin in
induction chemotherapy for relapsed childhood ALL, a large-
scale, multi-center, prospective study is now in progress in
Korea (27). 
In conclusion, results in this study suggest that a weekly
idarubicin dose of 10 mg/m2 in induction combination che-
motherapy for relapsed ALL is more effective and less toxic
than a dose of 12.5 mg/m2 for Korean children, mainly due
to low TRM. But remission for many patients after induction
chemotherapy was associated with a subsequent relapse of ALL,
and an unsatisfactory survival rate. A more intensive and effec-
tive post-remission treatment plan should be investigated.
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